Amplified Sciences is developing an ultra-sensitive diagnostic platform aimed at improving the early detection and risk stratification of pancreatic cysts, a key challenge in preventing pancreatic cancer.
The company’s lead product, PanCystPro™, uses a combination of three biomarkers—including the protease gastricsin, glucose, and CEA—along with machine learning algorithms to help distinguish potentially precancerous pancreatic cysts from benign lesions. The goal is to reduce both unnecessary surgeries and missed opportunities for early cancer intervention.
A graduate of the inaugural AGA Incubator cohort, Amplified Sciences has already launched early-access clinical sites and is collaborating with institutions including UCSF, Stanford, Indiana University, and UPMC.